Top Page
Bausch + Lomb Corporation
(NYSE:BLCO)
Bausch + Lomb Corporation (BLCO) vs. SPDR S&P 500 ETF (SPY)
Bausch + Lomb Corporation Business Overview & Revenue Model
Bausch + Lomb Corporation Key Performance Indicators (KPIs)
Measures revenue growth from existing operations, excluding acquisitions or currency effects, to reveal true performance and demand within each segment.
Main Street DataBausch + Lomb Corporation Earnings Call Summary
Bausch + Lomb Corporation Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.98B | 4.79B | 4.15B | 3.77B | 3.77B | 3.41B |
| Gross Profit | 2.96B | 2.92B | 2.50B | 2.25B | 2.30B | 2.13B |
| EBITDA | 509.00M | 601.00M | 499.00M | 598.00M | 733.00M | 732.00M |
| Net Income | -305.00M | -317.00M | -260.00M | 6.00M | 182.00M | -18.00M |
Balance Sheet | ||||||
| Total Assets | 13.83B | 13.47B | 13.44B | 11.14B | 10.82B | 11.27B |
| Cash, Cash Equivalents and Short-Term Investments | 310.00M | 305.00M | 331.00M | 354.00M | 174.00M | 238.00M |
| Total Debt | 4.95B | 4.94B | 4.56B | 2.44B | 112.00M | 101.00M |
| Total Liabilities | 7.33B | 6.92B | 6.52B | 4.04B | 1.42B | 1.28B |
| Stockholders Equity | 6.43B | 6.47B | 6.85B | 7.03B | 9.33B | 9.92B |
Cash Flow | ||||||
| Free Cash Flow | -196.00M | -59.00M | -198.00M | 170.00M | 664.00M | 263.00M |
| Operating Cash Flow | 169.00M | 232.00M | -17.00M | 345.00M | 873.00M | 522.00M |
| Investing Cash Flow | -452.00M | -412.00M | -2.11B | -215.00M | -214.00M | -256.00M |
| Financing Cash Flow | 255.00M | 178.00M | 2.08B | 81.00M | -712.00M | -232.00M |
Bausch + Lomb Corporation Technical Analysis
Bausch + Lomb Corporation Risk Analysis
Bausch + Lomb Corporation Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $5.19B | 44.81 | 8.30% | ― | 11.49% | -2.89% | |
72 Outperform | $13.94B | 34.51 | 5.01% | ― | 6.35% | 12.94% | |
68 Neutral | $6.58B | 42.36 | 9.81% | 0.25% | 9.19% | 23.06% | |
63 Neutral | $8.04B | 5,557.20 | 0.08% | ― | 11.74% | ― | |
56 Neutral | $5.51B | ― | -4.69% | ― | 6.23% | 17.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
39 Underperform | $2.23B | ― | -44.44% | 5.72% | -7.08% | -113.81% |
Bausch + Lomb Corporation Corporate Events
Bausch + Lomb Corporation is a leading global eye health company, operating in the vision care, pharmaceuticals, and surgical segments, dedicated to enhancing vision care worldwide. In its latest earnings report for the quarter ending September 30, 2025, Bausch + Lomb reported a slight increase in revenues compared to the previous year, with product sales reaching $1.277 billion. However, the company experienced a net loss of $28 million for the quarter, attributed to increased costs and expenses. Key financial metrics showed a rise in operating income to $95 million, despite a significant interest expense of $101 million. Looking ahead, Bausch + Lomb’s management remains focused on strategic initiatives and operational efficiencies to navigate economic challenges and enhance shareholder value.
The recent earnings call for Bausch + Lomb Corporation painted a positive picture, highlighting strong revenue growth across its key segments, particularly in Pharmaceuticals and Vision Care. Despite some concerns regarding gross margin and tariff impacts, the company showcased resilience through its recovery from the enVista recall and successful cash flow optimization, demonstrating strategic management and a promising outlook.
Bausch + Lomb Corporation reported a revenue of $1.281 billion for the third quarter of 2025, marking a 7% increase from the previous year. Despite a net loss of $28 million, the company showed strong growth in its Pharmaceuticals and Vision Care segments, with significant advancements in its R&D pipeline. The company continues to expand its leadership in the dry eye market and regain momentum in premium intraocular lenses, which is expected to enhance its market positioning and stakeholder confidence.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Bausch + Lomb Corporation announced it will release its third-quarter 2025 financial results on October 29, 2025, followed by a conference call and webcast to discuss the results and provide a business update. Additionally, the company will hold an investor day on November 13, 2025, to highlight its product pipeline and potential innovations, signaling a focus on future growth and industry leadership.
The most recent analyst rating on (BLCO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Bausch + Lomb announced the publication of a pivotal U.S. clinical trial for its enVista Envy full range of vision intraocular lens (IOL) in the American Journal of Ophthalmology. The trial results demonstrated that the enVista Envy IOL met all primary efficacy and safety endpoints, showing superior visual performance compared to the enVista monofocal IOL. The study highlighted the lens’s ability to provide a continuous range of vision and excellent tolerance to visual disturbances, positioning it as a promising option for cataract patients seeking comprehensive visual correction.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Bausch + Lomb announced the publication of a study in Clinical Ophthalmology demonstrating the effectiveness of XIIDRA, a prescription eye drop, in alleviating end-of-day eye dryness and discomfort for contact lens wearers. The study showed significant improvements in symptoms as early as two weeks, with continued use resulting in further symptom relief and increased comfortable contact lens wear time. These findings suggest XIIDRA as a viable alternative for those who do not find relief with over-the-counter options, potentially enhancing the company’s position in the eye care market.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Bausch + Lomb has launched the ASANA gas permeable lenses in the U.S., expanding its portfolio of specialty vision products. These lenses are designed for durability and enhanced visual acuity, particularly for patients with complex vision challenges such as astigmatism and keratoconus. The ASANA lenses offer eye care professionals a customizable and comprehensive range of options, supported by fast manufacturing and shipping, and a generous warranty program. This launch positions Bausch + Lomb as a versatile provider in the eye care industry, potentially enhancing its market presence and offering significant benefits to both eye care professionals and patients.
The most recent analyst rating on (BLCO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
On August 14, 2025, Bausch + Lomb Corporation announced the termination of the Amended and Restated Director Appointment and Nomination Agreement with Carl C. Icahn and his affiliates, following the Icahn Group’s reduced stake in Bausch Health Companies Inc. Consequently, Brett Icahn and Gary Hu resigned from the company’s board of directors. The resignations were not due to any disagreements with the company, and Bausch + Lomb’s CEO expressed gratitude for their contributions over the past three years.
The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Bausch + Lomb Corporation has announced its participation in two significant investor conferences in September 2025, namely the J.P. Morgan European Leveraged Finance Conference and the Morgan Stanley Global Healthcare Conference. This engagement highlights the company’s proactive approach in maintaining strong investor relations and could potentially impact its market positioning positively by showcasing its strategic initiatives and financial outlook to key stakeholders.
The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Bausch + Lomb Corporation’s recent earnings call painted a picture of robust performance in its Vision Care and Dry Eye segments, with significant strides in contact lenses and dry eye products. The company has raised its financial guidance in light of these achievements and successfully refinanced its debt. However, challenges persist, notably the enVista recall and a downturn in the U.S. Generics business, which have dampened overall performance.
Bausch + Lomb Corporation is a global leader in eye health, providing a wide range of products and services across three main segments: Vision Care, Pharmaceuticals, and Surgical. The company is a subsidiary of Bausch Health Companies Inc., with a significant presence on both the New York and Toronto Stock Exchanges under the ticker symbol ‘BLCO’.
Bausch + Lomb reported a revenue of $1.278 billion for the second quarter of 2025, marking a 5% increase from the previous year, driven by strong performance in its Vision Care segment. Despite a GAAP net loss of $62 million, the company raised its full-year guidance, reflecting solid business performance and the impact of foreign exchange. The company resumed full production of its enVista intraocular lenses following a voluntary recall and achieved significant growth in its dry eye portfolio, showcasing its robust pipeline and future potential.
The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.